Corporate Governance

Board of Directors

 

Acarix’s board of directors is the highest decision-making body after the general meeting of shareholders.

 

Philip Siberg

CHAIRMAN OF THE BOARD AND BOARD MEMBER SINCE 2021

Born: 1973

Education: Philip Siberg has a master's degree in engineering from KTH 1997, Mechanical Engineering and Industrial Economics.

Previous engagements/experience: Philip Siberg has 20 years of experience as international CEO and board work in public and unlisted companies in medtech and life science. Main occupation today is as President and co-founder of Coala Life Inc, a cardiac technology and platform venture active in algorithm-based remote monitoring and diagnostics. Philip is a Swedish citizen living in California, USA, since 2019.

Other significant ongoing assignments: Chairman of the board of Nasdaq First North-listed Senzime AB (publ.), CEO and deputy board member of Longmeadow Farm AB and advisor to start-up companies.

Acarix holdings: Shares: 0, Warrants: 0

Marlou Janssen-Counotte

Board member since 2020

Born: 1965.

Education: Marlou Janssen studied hotel management at TIO.

Previous engagements/experience: Marlou Janssen-Counotte has more than 25 years of experience from the medtech industry. She started her medtech career at Medtronic and, in the past 20 years, has held senior executive roles as Vice President at St. Jude Medical, Vice President International Marketing & Sales at Biotronik and President and Board member at Biotronik Inc.

Other significant ongoing assignments: Manages EDP Solutions at Philips Medical Systems.

Acarix holdings: No shares or warrants.

Ulf Rosén

BOARD MEMBER SINCE 2014

Born: 1960.

Education: Ulf Rosén is a registered nurse and has a degree in business administration from IHM Business School. He has also completed a number of traineeships, such as in financial management at INSEAD.

Previous engagements/experience: Since the late 1990s, Ulf Rosén has been Chairman of the Board, a Board member and CEO of a number of Scandinavian companies in the medical technology, pharma and service sectors. Previous positions include CEO of Neo-Pharma AB, CEO of Attana AB, Chairman of the Board of Trial Form Support International, Stille AB and Scibase AB, General Manager of Fresenius-Kabi AB, Executive Vice President of the Global Nutrition Division at Fresenius-Kabi, CEO of Pharmacia & Upjohn AS and CEO of Globen Ögonklinik AB. Ulf Rosén is co-founder of Lobsor Pharmaceuticals AB.

Other significant ongoing assignments: CEO of Lobsor Pharmaceuticals AB. Chairman of the Board and CEO of Intrance Holding AB, Intrance Medical Systems Inc, LobSor Holding AB and Ponscasa Holding AB. CEO of Ponscasa Denmark ApS and Board member of Reapplix ApS. General Partner for Fund III at the investment company SEED Capital, responsible for investments in medical technology and digital health solutions.

Acarix holdings: 965,830 shares and no warrants. Ulf Rosén represents SEED
Capital which owns approximately 3.4 per-cent of the company. 

Fredrik Buch

BOARD MEMBER SINCE 2021

Born: 1954.

Education: Fredrik Buch is a MD, specialist in orthopedics, University of Gothenburg, Sweden.

Previous engagements/experience: Fredrik Buch worked in the pharmaceutical industry with clinical trials and regulatory issues both in Europe and internationally at Squibb / Bristol Meyers, Hoechst and Pharmacia / Upjohn. Since then, he has been a fund manager at SEB Läkemedelsfonder and invested globally in pharmaceuticals and medical technology. The fund was under Fredrik Buch named by Forbes as one of the 50 best funds worldwide. Fredrik Buch then became a partner at HealthCap and worked with venture capital investments in life science. For the past 15 years, Fredrik has worked with board assignments and various types of consulting assignments.

Other significant ongoing assignments: Chairman of the Board at Huvudsta Vårdcentral AB, Citadellet Bolagsservice AB, Pila Pharma AB and Tridentify AB. Board member of Lantmännen Medical AB, Intrance Medical System Inc,  Lobsor Holding AB and Intrance Holding AB, Cytovac A / S.

Acarix holdings: Shares: 254 639, Warrants: 0